Regenxbio Inc’s recent filing unveils that its Officer VITTAL VASISTA acquired Company’s shares for reported $0.15 million on Dec 30 ’24. In the deal valued at $7.41 per share,20,041 shares were bought.
Then, KARABELAS ARGERIS N sold 10,000 shares, generating $101,052 in total proceeds. Upon selling the shares at $10.11, the Director now owns 11,286 shares.
Before that, KARABELAS ARGERIS N sold 10,000 shares. Regenxbio Inc shares valued at $115,588 were divested by the Director at a price of $11.56 per share. As a result of the transaction, KARABELAS ARGERIS N now holds 11,286 shares, worth roughly $75841.92.
Goldman downgraded its Regenxbio Inc [RGNX] rating to a Neutral from a a Buy in a research note published on February 11, 2025; the price target was decreased to $14 from $38.
Price Performance Review of RGNX
On Tuesday, Regenxbio Inc [NASDAQ:RGNX] saw its stock fall -3.03% to $6.72. Over the last five days, the stock has lost -11.35%. Regenxbio Inc shares have fallen nearly -13.07% since the year began. Nevertheless, the stocks have fallen -63.02% over the past one year. While a 52-week high of $28.80 was reached on 01/07/25, a 52-week low of $6.56 was recorded on 02/25/25. SMA at 50 days reached $7.74, while 200 days put it at $10.82.
Levels Of Support And Resistance For RGNX Stock
The 24-hour chart illustrates a support level at 6.48, which if violated will result in even more drops to 6.25. On the upside, there is a resistance level at 6.91. A further resistance level may holdings at 7.11. The Relative Strength Index (RSI) on the 14-day chart is 34.68, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.56, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.85%. Stochastics %K at 11.92% indicates the stock is a buying.
The most recent change occurred on June 07, 2024 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $38 price target.
